Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)

NCT03530215 · clinicaltrials.gov ↗

COMPLETED

Status

500000

Enrollment

OTHER

Sponsor class

Conditions

Cardiac Disease
Cancer

Interventions

DRUG: Antineoplastic and Immunomodulating Agents

Sponsor

Groupe Hospitalier Pitie-Salpetriere